FISCHER PHARMACEUTICALS LTD.’s TI-SCREEN NATURAL SUNSCREEN IS U.S. DEBUT

FISCHER PHARMACEUTICALS LTD.'s TI-SCREEN NATURAL SUNSCREEN IS U.S. DEBUT product by the Israeli dermatological product manufacturer's newly-acquired U.S. subsidiary, Fischer Pharmaceuticals, Inc. The parent firm recently purchased a 49% interest in Fischer (formerly T/I Pharmaceuticals) as an entry into the U.S. market. Fischer plans to begin promotions for the SPF 16 TI-Screen Natural sunscreen (active ingredient titanium dioxide) at the annual meeting of the American Academy of Dermatology in December. Fischer Pharmaceuticals, Ltd. has provided $250,000 to its subsidiary for working capital purposes and has assumed $1.4 mil. of T/I's $1.5 mil. in loans. Fischer plans to expand the firm's distribution; currently, two-thirds of the firm's business is in California. Fischer also plans to enlarge T/I's staff from its current 10 employees and relocate the company from Irvine to Sunnyvale, Calif. Hans Kaspar, who retired from SBH, formerly Sola Barnes-Hind, last June, is president and CEO of the U.S. operation. Kaspar, 62, was most recently VP-ophthalmic research at SBH and had worked for Barnes-Hind for 30 years, where he had been VP-R&D and international operations. In addition to TI-Screen sunscreens, U.S. Fischer products include TI-Cream moisturizer with hyaluronic acid for application on the face and neck and Ulactin body moisturizer with lactic acid and urea. Fischer Pharmaceuticals, Ltd. has manufacturing facilities in Tel Aviv and Germany. Three-quarters of the firm's $20 mil. in worldwide sales are generated in Israel. Company brands include Dr. Fischer baby care and lice treatment products and Ultrasol sunscreens.